"Didanosine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
Descriptor ID |
D016049
|
MeSH Number(s) |
D03.633.100.759.590.616.130 D13.570.230.500.090 D13.570.583.616.130 D13.570.800.573.130
|
Concept/Terms |
Didanosine- Didanosine
- Dideoxyinosine
- 2',3'-Dideoxyinosine
- 2',3' Dideoxyinosine
- ddI (Antiviral)
|
Below are MeSH descriptors whose meaning is more general than "Didanosine".
Below are MeSH descriptors whose meaning is more specific than "Didanosine".
This graph shows the total number of publications written about "Didanosine" by people in this website by year, and whether "Didanosine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 |
2017 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Didanosine" by people in Profiles.
-
Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. AIDS. 2019 03 15; 33(4):675-683.
-
New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes. AIDS. 2017 07 17; 31(11):1535-1543.
-
Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients. AIDS. 2001 Sep 07; 15(13):1729-31.